Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00327691 · ClinicalTrials.gov registry record · Phase 4
A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 8,600
- Enrollment target
NCT00327691 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 8,600 participants.
The verdict
NCT00327691, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 8,600 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the degree of additional reduction in cardiovascular risk that was accrued to patients by lowering their LDL-C beyond the currently accepted minimum target level for patients with pre-existing CHD. Secondary objectives include the safety profile of this treatment strategy, its cost-effectiveness, effect on other atherosclerotic-related events and procedures, and total mortality.
Interventions
- DRUG Atorvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,600 participants |
| Start Date | 1998-04 |
| Est. Completion | 2004-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00327691
The ClinicalTrials.gov registry entry for NCT00327691 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 8,600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atorvastatin is the first listed.
NCT00327691 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00327691 about?
NCT00327691 is a clinical study titled "A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels". The primary objective of this study is to determine the degree of additional reduction in cardiovascular risk that was accrued to patients by lowering their LDL-C beyond the currently accepted minimum target level for patients with pre-existing CHD. Secondary objectives include the safety profile of...
What is the current status of trial NCT00327691?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 8,600 participants. The study started on 1998-04. Estimated completion is 2004-08.
What interventions are being tested in trial NCT00327691?
The interventions under investigation include: Atorvastatin (DRUG).
Who is sponsoring clinical trial NCT00327691?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.